Background Rotavirus is the most prevalent cause of severe gastroenteritis, hospitalizations, and deaths among infants and young children, globally. No specific antiviral drug is available against rotavirus infection. Objective The current study aimed to assess the antiviral effect of human cathelicidin antimicrobial peptide LL-37 on rotavirus infection in vitro. Methods This study was conducted in the laboratory conditions of Iran University of Medical Sciences, in Tehran City, Iran. The neutral red assay was performed to assess the cytotoxicity of different concentrations of the peptide on the MA-104 cell line, and its antiviral activity was determined by TCID50 (50% tissue culture infective dose) assay. Findings According to the cytotoxicity results, viability maintained more than 90% up to the concentration of 50 μg/mL of LL-37 peptide. The antiviral assays results revealed that the concentration of 50 μg/mL LL-37 peptide could significantly reduce (3.36 log10 TCID50) the production of rotavirus progeny when administered before virus exposure (P= 0.0001). However, no inhibitory effect was detected after cell exposure to virus. Conclusion The obtained data suggested that LL-37 can be considered as a new antiviral agent for protecting infants and young children against gastroenteritis caused by rotaviruses. However, further in vivo investigations are required to confirm this finding.
Introduction
otavirus infection is the most common cause of severe gastroenteritis among children under 5; it is responsible for 440000 deaths worldwide annually. Currently, no effective antiviral drug or specific treatment exists for this infection [1, 2] . Hence, the development of novel thera-peutics is of significant interest. The present in vitro study aimed to evaluate the antiviral activity of the only human cathelicidin LL-37 antimicrobial peptide against rotavirus infection.
Materials and Methods
The rotavirus stock was prepared by infecting the cell monolayers with the virus at the multiplicity of infection (MOI) of 1 ( rus titer was then determined by tissue culture infectious dose 50 (TCID50), according to the Reed and Muench method [24] . We used the neutral red uptake assay to evaluate the cytotoxicity of LL-37 peptide on MA-104 cells. Optical density (OD) was subsequently measured at 550 nm using a microplate reader. We also examined the in vitro antiviral potency of the LL-37 against rotavirus infection before and after the infection.
For pre-treatment assay, the rotavirus stock was serially diluted in DMEM (dulbecco's modified eagle medium) to prepare 100 TCID50/mL of rotavirus suspension. The media were then removed, and the cultured cells were washed with phosphate buffer saline (PBS). Next, the cells were pre-treated with the different non-cytotoxic concentrations of the LL-37 for 3 hours before the infection. After that, the peptide solutions were removed, and cells were washed with PBS, and then infected with 100 TCID50/mL of rotavirus. After one hour incubation, the inoculums were discarded, the cells were washed with PBS to remove any unattached virus, and overlaid with the serum-free medium at 37°C in 5% CO2 for 72 hours.
For post-treatment assay, the monolayers were washed with PBS and then incubated with 100 TCID50 of rotavirus suspension. After one hour incubation, the inoculums were discarded, and LL-37 in serum-free DMEM was added at various non-toxic concentrations. Finally, the treated cells were placed at 37°C in 5% CO2 for 72 hours.
The plates were being observed by inverted microscope daily to detect any prevention of cytopathic effect (CPE) by the peptide. At post-72 hours incubation time (when virus control produced an obvious CPE), virus titer was calculated by the TCID50 method. Statistical analyses were performed using the GraphPad Prism. Statistical significance was assessed using the one-way analysis of variance (ANOVA) and P-values less than 0.05 were considered statistically significant.
Results
The cells were treated with various peptide concentrations to examine cytotoxicity. According to the results, LL-37 (up to 50 μg/mL) produced no toxicity in MA-104 cells, and cell viability was maintained above 90% up to 50 µg/mL of LL-37. Therefore, LL-37 was used in activities related to antiviral assays (AVA) at concentrations showing ≤10% cytotoxicity. To assess the antiviral potential of LL-37 against rotavirus, different concentrations of the peptide before/after infection with rotavirus treated cells, and then assessed by determination of viral titer by TCID50 after 72 hours.
According to the findings, LL-37, when cells were exposed to the peptide before virus infection, significantly inhibited the CPE associated with rotavirus infection in infected cells in vitro. That is LL-37 pre-treatment (50 μg/ mL) of MA-104 cells resulted in a significant reduction of CPE as rotavirus shows a distinct CPE characterized by cell rounding, detachment of cells from the monolayer, and lytic foci. The CPE formation was affected by peptide pretreatment of monolayers before infection. In contrast, treatment of rotavirus-infected MA-104 cells (post-infection) had minimal impact on rotavirus infection. Moreover, this pre-infection exposure of cells to LL-37 resulted in a significant, concentration-dependent reduction in infectivity when compared with the virus alone, so that three hours pre-treatment of cells with 50 μg/mL LL-37 before infection reduced virus titer by 3.36 log10 TCID50 compared to the virus control group (P=0.0001).
Conclusion
Differences in the efficacy of LL-37 at reducing rotavirus infection before and after the infection may be partly due to the time of addition and mainly to the LL-37 mode of action. One possible hypothesis may be masking of epithelial cell surface receptors, which prevents attachment and subsequent virus entry into the cells [27] . Although the present study has been one of the first attempts to examine the antiviral activity of LL-37 peptide against a nonenveloped virus, the specific mechanism(s) by which LL-37 acts against rotavirus is not fully understood yet. Some evidence suggests the involvement of activities other than direct damage to viral envelopes [30] . To sum up, it seems that LL-37 peptide may be utilized as a prophylactic agent in the management of acute rotavirus gastroenteritis. However, further in vivo investigations are required to confirm the present findings.
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